You are running an unsupported browser, please upgrade your browser. Close

Email Subscription

Never miss the latest news and offers - subscribe now!

Never miss the latest news and offers - subscribe now!

Privacy Policy and Cookies

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

What Is Gene Therapy? How Does It Save and Improve the Quality of Life?

March 28, 2019

What Is Gene Therapy?

 

Gene therapy is a new and exciting technique, defined as the use of genetic material to cure or alleviate disease. It is considered revolutionary, yet still in its infancy, with many new therapies currently undergoing clinical trials. 

 

Gene therapy has the potential to transform the treatment for diseases, significantly changing how doctors manage and treat patients. 

 

 

Two Types of Gene Therapy

 

There are two main types of gene therapy. 

 

The first corrects a specific disease causing genetic mutation. These are targeted towards inherited genetic disorders such as hemophilia or Duchenne muscular dystrophy. The second gives new functions to cells allowing them to fight disease.

 

A good example of these therapies are chimeric antigen receptor T cell (CAR-T) therapies. Both Novartis’ Kymriah and Gilead’s Yescarta are examples of CAR-T therapies, that have demonstrated exceptional cancer remission rates where other forms of treatment have failed.

 

Cancer is the by far the largest category of disease with 65% of gene therapy clinical trials being investigated, followed by 11.1% for inherited monogenetic disease, 7% for infectious disease, and 6.9% for cardiovascular disease1.

 

How Does Genetic Material Get Delivered to Host Cell(s)?

 

Genetic material gets delivered to a host cell via a delivery system known as a vector. Vectors deliver genetic material via one of the two methods. By directly injecting genetic material into the patient (in vivo), and where selected cells collected from the patient, undergo modification outside (ex vivo) before introducing them back into the patient.

 

The most commonly used type of vector is a virus. While there are other methods of delivering genetic material into a cell, viruses have now been developed that demonstrate a good balance between efficacy and safety. 

 

 

Commercially Successful Gene Therapies

 

Developing a commercially successful gene therapy is challenging. It requires balancing several different considerations. Having a clinical effective therapy is essential, but this alone is not sufficient to ensure product success. In addition to this, reimbursement, quality and regulatory considerations, and manufacturing also must be considered. 

 

To date, a total 11 gene therapies have received marketing approval. However, behind this there is a strong clinical pipeline with >1000 clinical trials underway, and 92 drugs in Phase 32.

 

Furthermore, there has been significant investment with >$50B being invested in the area in the past 3 years3.

 

This investment, coupled with the accelerating understanding of disease at the genetic level, holds immense potential. Academic, commercial manufacturers, and industry suppliers are actively seeking new approaches that deliver these therapies as quick as possible to a waiting population.

 

 

References:


 Key Considerations for Gene Therapy Commercialization, Cell Culture Dish, September 12, 2018
2 2019 Cell & Gene Therapies State of the Industry Briefing, Alliance for Regenerative Medicine, January 7, 2019
3 Annual Regenerative Medicine Data Report, Alliance for Regenerative Medicine, 2016-2018

What Is Gene Therapy? How Does It Save and Improve the Quality of Life?

Clive Glover – Senior Global Marketing Manager, Cell & Gene Therapy

Dr Clive Glover is a Senior Global Marketing Manager of Cell & Gene Therapy at Pall Biotech. Clive leads Pall’s cell and gene therapy business. He has over 15 years of experience in cell and gene therapy. His work has been published in numerous scientific journals, and he has presented at many conferences.
Dr Clive Glover is a Senior Global Marketing Manager of Cell & Gene Therapy at Pall Biotech. Clive leads Pall’s cell and gene therapy business. He has over 15 years of experience in cell and gene therapy. His work has been published in numerous scientific journals, and he has presented at many conferences.
Read more
  • Category
  • Author
  • Sort By
Results